Facebook Pixel Code
Banner image
About the Institute

Scientific Advisory Board

SickKids Scientific Advisory Board (SAB) is comprised of internationally respected research leaders. The SAB advises the Chief of Research, the CEO and the hospital’s board, in order to build on scientific excellence at SickKids. The SAB provides advice on the strategic direction of the Research Institute, helps to establish and monitor key performance indicators, provides feedback on the strengths and areas for development for the Research Institute and leads external reviews of the seven research programs.

SickKids Scientific Advisory Board members:

Dr. Stephen K. Burley
Director, Center for Integrative Proteomics Research, Associate Director, RCSB-PDB, Distinguished Professor, Department of Chemistry and Chemical Biology; Member, Cancer Institute of New Jersey

Stephen Burley is an expert in structural biology and proteomics, structure/fragment based drug discovery, and clinical medicine/oncology. Burley currently serves as a Distinguished Professor in the Department of Chemistry and Chemical Biology and Director of the Center for Integrative Proteomics Research, and Director of the BioMaPS Institute for Quantitative Biology at Rutgers, The State University of New Jersey. He is also Associate Director of the Research Collaboratory for Structural Bioinformatics Protein Data Bank, and a Member of the Rutgers Cancer Institute of New Jersey. From 2008 to 2012, Burley was a Distinguished Lilly Research Scholar in Lilly Research Laboratories. 

Prior to joining Lilly, Burley served as the Chief Scientific Officer of SGX Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Lilly in 2008. Until 2002, Burley was the Richard M. and Isabel P. Furlaud Professor at The Rockefeller University, and an Investigator in the Howard Hughes Medical Institute. He has authored or coauthored more than 200 scholarly scientific articles. He is a Fellow of the Royal Society of Canada and of the New York Academy of Sciences. Burley received an MD degree from Harvard Medical School in the joint Harvard-MIT Health Sciences and Technology program and, as a Rhodes Scholar, received a D.Phil. in Molecular Biophysics (structural biology) from Oxford University. He trained in internal medicine at the Brigham and Women's Hospital, and did post-doctoral work with William N. Lipscomb at Harvard University and Gregory A. Petsko at the Massachusetts Institute of Technology. With William J. Rutter and others at the University of California, San Francisco and Rockefeller, Burley co-founded Prospect Genomics, Inc., which was acquired by SGX in 2001.


Dr. Elaine Fuchs
HHMI Investigator and Rebecca C. Lancefield Professor, T​he Rockefeller University            

Elaine Fuchs is a renowned for her research in skin biology, its stem cells and associated genetic disorders, including cancers. She received her PhD in biochemistry from Princeton. After postdoctoral research at MIT, she joined the faculty at University of Chicago. In 2002, she relocated to Rockefeller University, where she is the Rebecca C. Lancefield professor of Mammalian Cell Biology and Development. She has been an Investigator of the Howard Hughes Medical Institute since 1988. 

Fuchs’ awards and honours include the Richard Lounsbery Award from the National Academy of Sciences, National Medal of Science, L’Oreal-UNESCO Award, Albany Prize in Medicine, March of Dimes Prize in Developmental Biology, Pasarow Award in Cancer, Pezcoller Award in Cancer Research, EB Wilson Award, and in 2017 will receive the Vanderbilt Prize. Fuchs is an elected member of the National Academy of Sciences, National Academy of Medicine (formerly Institute of Medicine), American Philosophical Society and European Molecular Biology Organization (foreign member). She holds honorary doctorates from NYU School of Medicine, University of Illinois, Albany Medical College and Harvard University. She is past-President of American Society for Cell Biology, The International Society for Stem Cell Research and the Harvey Society, and serves on the NYAS Board of Governors and NAM/IOM Council. She’s trained >25 graduate students and 100 postdocs, most now at academic universities and medical schools. 


Dr. Martin Osmond
CEO and Scientific Director, Children’s Hospital of Eastern Ontario Research Institute (CHEO RI), Vice​-President of Research, CHEO, Professor of Pediatrics, University of Ottawa and Senior Scientist, CHEO RI

Dr. Osmond graduated from McGill University medical school in 1986.  He completed a Family Medicine Residency in 1988, and a Pediatric Residency in 1992 at the University of Ottawa.  In 1994, he completed a Pediatric Emergency Fellowship at CHEO. His clinical work is as a pediatric emergency physician at CHEO

His areas of research interest are the evaluation and management of pediatric head injuries and the use of prehospital care in the treatment of ill and injured children.  He is also a co-principal investigator in a CIHR-funded study of children with concussion presenting to the ED – this study aims to predict those who will suffer severe post-concussion syndrome in hopes of designing interventions for at-risk children to improve their outcomes.


Dr. Bonnie Ramsey
Director, Center for Clinical and Translational Research, Associate Director, Pediatric Clinical Research Center

Bonnie W. Ramsey, MD, is director of the Center for Clinical and Translational Research at Seattle Childrens Research Institute. She is the co-PI of the UW Institute for Translational Health Sciences which provides extensive clinical research infrastructure at Seattle Childrens Hospital. She is also the PI for a P30 for Cystic Fibrosis Research from the NIDDK. She is Professor and Vice Chair for research in the Department of Pediatrics and holds the Endowed Chair in Cystic Fibrosis (CF) at the University of Washington School of Medicine.


Dr. David Rowitch
Department of Neurological Surgery, Professor of Pediatrics and Neurological Surgery; Chief of Neonatology, Howard Hughes Medical Institute Investigator University of California San Francisco

Dr. David Rowitch is chief of neonatology at UCSF. Rowitch earned his medical degree from the University of California, Los Angeles and doctorate in biochemistry from the University of Cambridge in England. Subsequently, he completed an internship and residency in pediatrics and fellowship in newborn medicine at Children's Hospital in Boston. Rowitch was a postdoctoral fellow at Harvard College in the laboratory of Andrew P. McMahon. He began his own laboratory at Dana-Farber Cancer Institute in Boston and was a Harvard Medical School faculty member an Attending Neonatologist at Children's Hospital, Boston, from 1996-2006. By applying principles of basic brain development, we may be able to better understand the neurological problems faced by premature infants as well as others central nervous system disorders such as multiple sclerosis and brain cancer. 

Dr. Rowitch leads a laboratory in the UCSF Institute for Regeneration Medicine that investigates genetic factors that determine cellular development in neural stem cells of the brain and the response to injury. His work in the field of neurobiology has earned him numerous awards, including the National Institute of Health Clinical Investigator Award, Basil O'Connor Starter Scholar Award from the March of Dimes Foundation, Kimmel Foundation Scholar Award and the James S. McDonnell Foundation Research Award. He was appointed a Howard Hughes Medical Institute Investigator in 2008​.